drugset / Trial / NCT06163898
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of alnuctamab in combination with mezigdomide in participants with relapsed and/or refractory multiple myeloma.
Timeline
- Start
- 2024-02-27
- Primary completion
- 2025-06-03
- Completion
- 2025-06-03
Outcome
Outcome not reported
Stopped (Business): “Business objectives have changed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alnuctamab | Protein / enzyme biologic | — | — |
| Subject | Mezigdomide | Small molecule | — | — |
| Background | Dexamethasone | Small molecule | — | — |